Baird analyst Michael Ha raised the firm’s price target on Privia Health (PRVA) to $26 from $24 and keeps an Outperform rating on the shares. The firm sees minimal incremental buyers of stocks in the managed care and healthcare facilities group until the policy overhang clears. Baird does not not expect guidance raises as it believes companies will maintain 2025 “conservatism and cushion” given potential Part D and macro headwinds that may evolve later this year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health price target lowered to $28 from $30 at Truist
- Privia Health price target raised to $23 from $21 at Barclays
- Privia Health enters Arizona in partnership with Integrated Medical Services
- Buy Rating for Privia Health Group: Stability and Growth Amid Medicare Model Changes
- Privia Health Group: Strong Execution and Growth Potential with Revised Price Target